Zhe-Bin Yu1, Yao Zhu1, Die Li1, Meng-Yin Wu1, Meng-Ling Tang1, Jian-Bing Wang2,3, Kun Chen4,5. 1. Division of Epidemiology and Health Statistics, Department of Public Health, Zhejiang University School of Medicine, 866 Yuhangtang Road, Hangzhou,, Zhejiang, 310058, China. 2. Division of Epidemiology and Health Statistics, Department of Public Health, Zhejiang University School of Medicine, 866 Yuhangtang Road, Hangzhou,, Zhejiang, 310058, China. wangjianbing@zju.edu.cn. 3. Research Center for Air Pollution and Health, Zhejiang University, Zhejiang, Hangzhou, China. wangjianbing@zju.edu.cn. 4. Division of Epidemiology and Health Statistics, Department of Public Health, Zhejiang University School of Medicine, 866 Yuhangtang Road, Hangzhou,, Zhejiang, 310058, China. ck@zju.edu.cn. 5. Cancer Institute, The Second Affiliated Hospital/Department of Public Health, Zhejiang University School of Medicine, 866 Yuhangtang Road, Hangzhou,, Zhejiang, 310058, China. ck@zju.edu.cn.
Abstract
AIMS/HYPOTHESIS: The aim of this study was to investigate the association between visit-to-visit variability in HbA1c and cognitive function decline in the elderly population. METHODS: We performed a pooled analysis of two prospective population-based cohorts (the Health Retirement Study [HRS] and the English Longitudinal Study of Ageing [ELSA]). Cognitive function, including memory and executive function, were assessed at baseline and every 2 years, while HbA1c levels were assessed at baseline and every 4 years. Visit-to-visit variability (VVV) in HbA1c was calculated using the CV, SD and variation independent of the mean (VIM) during the follow-up period. Linear mixed models were used to evaluate the association between HbA1c variability and cognitive function decline with adjustment for demographics, mean HbA1c, education, smoking, alcohol consumption, BMI, baseline hypertension, baseline diabetes status and HDL-cholesterol. RESULTS: The study enrolled 6237 participants (58.23% women, mean age 63.38 ± 8.62 years) with at least three measurements of HbA1c. The median follow-up duration was 10.56 ± 1.86 years. In the overall sample, compared with the lowest quartile of HbA1c variability, participants in the highest quartile of HbA1c variability had a significantly worse memory decline rate (-0.094 SD/year, 95% CI -0.185, -0.003) and executive function decline rate (-0.083 SD/year, 95% CI -0.125, -0.041), irrespective of mean HbA1c values over time. Among individuals without diabetes, each 1-SD increment in HbA1c CV was associated with a significantly higher rate of memory z score decline (-0.029, 95% CI -0.052, -0.005) and executive function z score decline (-0.049, 95% CI -0.079, -0.018) in the fully adjusted model. CONCLUSIONS/ INTERPRETATION: We observed a significant association between long-term HbA1c variability and cognitive decline among the non-diabetic population in this study. The effect of maintaining steady glucose control on the rate of cognitive decline merits further investigation.
AIMS/HYPOTHESIS: The aim of this study was to investigate the association between visit-to-visit variability in HbA1c and cognitive function decline in the elderly population. METHODS: We performed a pooled analysis of two prospective population-based cohorts (the Health Retirement Study [HRS] and the English Longitudinal Study of Ageing [ELSA]). Cognitive function, including memory and executive function, were assessed at baseline and every 2 years, while HbA1c levels were assessed at baseline and every 4 years. Visit-to-visit variability (VVV) in HbA1c was calculated using the CV, SD and variation independent of the mean (VIM) during the follow-up period. Linear mixed models were used to evaluate the association between HbA1c variability and cognitive function decline with adjustment for demographics, mean HbA1c, education, smoking, alcohol consumption, BMI, baseline hypertension, baseline diabetes status and HDL-cholesterol. RESULTS: The study enrolled 6237 participants (58.23% women, mean age 63.38 ± 8.62 years) with at least three measurements of HbA1c. The median follow-up duration was 10.56 ± 1.86 years. In the overall sample, compared with the lowest quartile of HbA1c variability, participants in the highest quartile of HbA1c variability had a significantly worse memory decline rate (-0.094 SD/year, 95% CI -0.185, -0.003) and executive function decline rate (-0.083 SD/year, 95% CI -0.125, -0.041), irrespective of mean HbA1c values over time. Among individuals without diabetes, each 1-SD increment in HbA1c CV was associated with a significantly higher rate of memory z score decline (-0.029, 95% CI -0.052, -0.005) and executive function z score decline (-0.049, 95% CI -0.079, -0.018) in the fully adjusted model. CONCLUSIONS/ INTERPRETATION: We observed a significant association between long-term HbA1c variability and cognitive decline among the non-diabetic population in this study. The effect of maintaining steady glucose control on the rate of cognitive decline merits further investigation.
Authors: Yoichiro Hirakawa; Hisatomi Arima; Sophia Zoungas; Toshiharu Ninomiya; Mark Cooper; Pavel Hamet; Giuseppe Mancia; Neil Poulter; Stephen Harrap; Mark Woodward; John Chalmers Journal: Diabetes Care Date: 2014-05-08 Impact factor: 19.112
Authors: M A E Baars; M P J van Boxtel; J B Dijkstra; P J Visser; M van den Akker; F R J Verhey; J Jolles Journal: Dement Geriatr Cogn Disord Date: 2009-02-07 Impact factor: 2.959
Authors: Justin B Echouffo-Tcheugui; Songzhu Zhao; Guy Brock; Roland A Matsouaka; David Kline; Joshua J Joseph Journal: Diabetes Care Date: 2019-01-18 Impact factor: 19.112
Authors: Julia M Hermann; Hans-Peter Hammes; Birgit Rami-Merhar; Joachim Rosenbauer; Morten Schütt; Erhard Siegel; Reinhard W Holl Journal: PLoS One Date: 2014-03-07 Impact factor: 3.240
Authors: Andreea M Rawlings; A Richey Sharrett; Thomas H Mosley; Shoshana H Ballew; Jennifer A Deal; Elizabeth Selvin Journal: Diabetes Care Date: 2017-05-12 Impact factor: 19.112
Authors: Ramit Ravona-Springer; Anthony Heymann; James Schmeidler; Erin Moshier; Elizabeth Guerrero-Berroa; Laili Soleimani; Mary Sano; Derek Leroith; Rachel Preiss; Ruth Tzukran; Jeremy M Silverman; Michal Schnaider Beeri Journal: Diabetes Care Date: 2017-06-20 Impact factor: 19.112